Prosecution Insights
Last updated: November 04, 2026
Application No. 18/706,116

TRI-, TETRA AND PENTAPEPTIDES, COMPOSITIONS THEREOF AND THEIR USE IN THE THERAPY OF PSORIASIS

Non-Final OA §101§102§112
Filed
Apr 30, 2024
Priority
Nov 02, 2021 — NO 20211318 +3 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Enumita AS
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
5m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
463 granted / 757 resolved
+1.2% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
58 currently pending
Career history
820
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
34.5%
-5.5% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 757 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Applicant's election with traverse of SEQ ID NO: 5 and the composition of Example 2 (SEQ ID NO: 5 and a moisturizer) in the reply filed on 8/31/2026 is acknowledged. The traversal is on the ground(s) that all peptide species listed in claim 11 were evaluated in the same assay and reported to exhibit the same inhibitory activity against formation of Pso p27, supporting the existence of a common technical relationship and common inventive concept across the claimed peptide family. This is not found persuasive because the technical feature of the claims is a tripeptide or tetrapeptide comprising 2 acidic amino acids and proline. However, this technical feature is not a special technical feature as it does not make a contribution over the prior art in view of Abiko et al. (see rejection under 35 U.S.C. 102(a)(1) below). Therefore, the requirement for election of species is proper under PCT Rule 13.1. The requirement is still deemed proper and is therefore made FINAL. Claims 6 and 12-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 8/31/2026. Status of the Claims Claims 1-9 and 11-15 are pending in this application. Claims 6 and 12-13 are withdrawn from consideration as being drawn to a non-elected species. Claims 1-5, 7-9, 11 and 14-15 are presently under consideration as being drawn to the elected species. Information Disclosure Statement The information disclosure statement filed on 8/21/2024 fails to comply with 37 CFR 1.98(a)(3)(i) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each reference listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered. Claim Objections Claims 4 and 11 are objected to because of the following informalities: In claim 1 the word “profylaxis” is misspelled. Claim 4 should be amended to recite “A composition…”. With respect to claim 11, each instance of “SEQ ID NO.” should be replaced with “SEQ ID NO:” Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-3, 5, 7-9, 11 and 14-15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claims recite a use without any active, positive steps delimiting how this use is actually practiced (see MPEP 2173.05(q)). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3, 5, 7-9, 11 and 14-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1-3, 5, 7-9, 11 and 14-15 recite a use without any active, positive steps delimiting how this use is actually practiced (see MPEP 2173.05(q)). Claims 2-3 and 5 are drawn to the peptide of claim 1 comprising various compositions. While a composition can comprise a peptide, a peptide cannot comprise a composition. Therefore, claims 2-3 and 5 are indefinite. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 7 recites the broad recitation “wherein the amino acid sequence comprises not more than 2 acidic amino acids”, and the claim also recites “preferably the amino acid sequence comprises 2 acidic amino acids” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 9 recites the limitation "the neutral or basic amino acid" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. Claim 14 recites the limitation "the composition" in line 1. There is insufficient antecedent basis for this limitation in the claim. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 14 recites the broad recitation “wherein the composition further comprises one or more pharmaceutically inactive or acceptable components or conventional additives”, and the claim also recites “preferably said one or more pharmaceutically inactive or acceptable components or conventional additives are selected….” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Regarding claim 14, the phrases "e.g." render the claim indefinite because it is unclear whether the limitation(s) following the phrases are part of the claimed invention. See MPEP § 2173.05(d). Furthermore, claim 14 recites “…and the like”. The metes and bounds of said phrase are indefinite. One of ordinary skill in the art would not know what is encompassed by the claim. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 15 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 15 is drawn to the peptide of claim 1, wherein the mammal is a human. It is noted that “[d]uring examination, statements in the preamble reciting the purpose or intended use of the claimed invention must be evaluated to determine whether the recited purpose or intended use results in a structural difference (or, in the case of process claims, manipulative difference) between the claimed invention and the prior art. If so, the recitation serves to limit the claim” (MPEP 2111.02). In the instant case, the limitation “for use in prophylaxis, prevention, inhibition and/or treatment of psoriasis of a mammal” is an intended use of the product and is not given any patentable weight. Therefore, since the limitation “wherein the mammal is human” does not limit the peptide of claim 1, claim 15 fails to further limit the subject matter of claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4, 7-9, 11 and 15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Abiko et al. (Chemical & Pharmaceutical Bulletin (1984), 32(1),228-36). With respect to claims 1-3, 7-9, 11 and 15, it is noted that “[d]uring examination, statements in the preamble reciting the purpose or intended use of the claimed invention must be evaluated to determine whether the recited purpose or intended use results in a structural difference (or, in the case of process claims, manipulative difference) between the claimed invention and the prior art. If so, the recitation serves to limit the claim” (MPEP 2111.02). In the instant case, the limitation “for use in prophylaxis, prevention, inhibition and/or treatment of psoriasis of a mammal” is an intended use of the product and is not given any patentable weight. With respect to claims 1, 7-9 and 11, Abiko et al. teach the peptide H-Asp-Lys- Pro- Asp-OH (abstract; Figs. 2-3), which corresponds to instantly claimed SEQ ID NO: 13. To advance prosecution, claims 2-3 have been interpreted as being drawn to compositions comprising the peptide of claim 1. With respect to claims 2-3, Abiko et al. teach that the peptide H-Asp-Lys- Pro- Asp-OH was dissolved in AcOH (page 234, 6th para). AcOH is pharmaceutically acceptable for use in topical cosmetic compositions. Therefore, claims 2-3 are anticipated. With respect to claim 4, Abiko et al. teach that the peptide H-Asp-Lys- Pro- Asp-OH was lyophilized (page 234, 6th para), thus reading on the claimed “powders”. With respect to claim 15, it is noted that, as discussed above under 35 U.S.C. 112(d), this claim does not further limit claim 1. Therefore, claim 15 is anticipated. Allowable Subject Matter SEQ ID NO: 5 is free of the prior art. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Apr 30, 2024
Application Filed
Aug 13, 2026
Interview Requested
Aug 19, 2026
Applicant Interview (Telephonic)
Aug 26, 2026
Examiner Interview Summary
Oct 21, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780871
POLYPEPTIDES RV3 AND RV4 HAVING ANTI-AGING FUNCTION AND APPLICATIONS THEREOF
4y 7m to grant Granted Nov 03, 2026
Patent 12780877
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 1m to grant Granted Nov 03, 2026
Patent 12751991
METHODS FOR TREATING PANCREATIC CANCER AND OTHER SOLID TUMORS
3y 11m to grant Granted Oct 06, 2026
Patent 12753206
VIPR2 ANTAGONIST PEPTIDE
4y 0m to grant Granted Oct 06, 2026
Patent 12735464
C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof
6y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
93%
With Interview (+32.2%)
2y 11m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 757 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month